Quercetin

槲皮素

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameQuercetin
Drug Alias NameQuertine栎精poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin槲皮苷3,3′,4′,5,7-pentahydroxyflavone +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFree radicals scavengersantioxidantPlatelet aggregation inhibitors +[6] 
TargetsFree radicalsTyrosine-protein kinase FRKThromboxane A2 synthase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaCognitive Dysfunction +[46] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTunisia +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesQuercegen Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesQuercegen PharmaceuticalsUT Health San AntonioNational Institutes Of Health +[21] 
Inactive CompaniesThe Brigham and Women's HospitalIncor Heart InstituteUniversity Of Michigan +[11] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaCognitive Dysfunction +[30] 
Inactive IndicationsHyperuricemiaDiabetes Mellitus, Type 2Coronary Disease +[16] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG